



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

외과학 석사 학위논문

한국 여성 유방암 코호트에서 ACOSOG  
Z0011 연구 결과의 유효성 확인  
**Retrospectively validating the results of the  
ACOSOG Z0011 trial in a large Korean  
Z0011-eligible cohort**

2018 년 10 월

서울대학교 대학원

의학과 외과학 전공

정 지 응



한국 여성 유방암 코호트에서 ACOSOG  
Z0011 연구 결과의 유효성 확인  
Retrospectively validating the results of the  
ACOSOG Z0011 trial in a large Korean  
Z0011-eligible cohort

지도교수 한 원 식

이 논문을 외과학 석사 학위논문으로 제출함  
2018 년 10 월

서울대학교 대학원  
의학과 외과학 전공  
정 지 응

정지응의 석사 학위논문을 인준함  
2019 년 01 월

위 원 장 \_\_\_\_\_(인)

부 위 원 장 \_\_\_\_\_(인)

위 원 \_\_\_\_\_(인)



# Abstract

## **Retrospectively validating the results of the ACOSOG Z0011 trial in a large Korean Z0011-eligible cohort**

Jung, Jiwoong

Department of Surgery

The Graduate School

Seoul National University

**Objective:** This study aimed to validate the Z0011 results within a Korean Z0011-eligible cohort and determine whether the number of sentinel lymph nodes (SLNs) influenced the Z0011-based outcomes.

**Summary Background Data:** The Z0011 trial demonstrated that axillary dissection (ALND) could be omitted during breast-conserving therapy for cT1-2N0 breast cancers with 1–2 metastatic SLNs. However, that result has not been validated in a larger cohort and the significance of the small number of SLNs remains unclear.

**Methods:** Data from Korean patients who fulfilled the Z0011 criteria were collected from 5 hospitals. Disease recurrence (DR) was compared between patients who underwent ALND or SLN dissection (SLND) alone. Propensity-score matching was performed to reduce the effects of potential selection biases.

**Results:** During 2010–2016, 1,750 Korean patients had 1–2 SLN metastases and fulfilled the Z0011 criteria. These patients included 707 cases treated using SLND alone (40%) and 967 patients with  $\leq 2$  SLNs (55%). Ninety-five patients (5.4%) experienced DR at a median interval

of 50 months, although the rates of DR were similar in the ALND and SLND groups. The adjusted hazard ratios for DR after ALND omission were 0.95 (95% CI: 0.55–1.64) among the entire cohort and 0.83 (95% CI: 0.34–2.03) among patients with  $\leq 2$  SLNs.

**Conclusions:** In this Korean Z0011-eligible cohort, ALND omission did not increase risk of DR, even among patients with  $\leq 2$  SLNs. Therefore, the Z0011 strategy might be safely applied in Asia, and a small number of SLNs did not significantly influence this strategy.

.....

**Key words : axillary lymph node dissection, breast cancer, sentinel lymph node biopsy**

***Student Number : 2016-21926***

# 목 차

1. INTRODUCTION .....	8
2. METHODS .....	9
2-1. Selection of the Z0011-eligible cohort .....	9
2-2. Study end-point .....	9
2-3. Statistical analyses .....	10
3. RESULTS .....	10
3-1. Characteristics of the Korean Z0011-eligible cohort .....	10
3-2. Characteristics of the SLND alone group from the Korean Z0011- eligible cohort .....	11
3-3. Outcomes in the Korean Z0011-eligible cohort .....	12
3-4. Comparison of disease recurrence after PS matching .....	13
4. DISCUSSION .....	14
5. CONCLUSION .....	18
6. REFERENCES .....	19



# INTRODUCTION

Axillary management of breast cancer has evolved based on the development of adjuvant therapies, which range from less extensive treatments to conventional axillary lymph node dissection (ALND). The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated that clinically node-negative women with T1–T2 invasive breast cancer experienced excellent local control and survival (based on a median follow-up of 6.4 years) after sentinel lymph node dissection (SLND) without ALND, as part of breast-conserving surgery (BCT) with whole-breast irradiation, even if metastases were present in 1–2 sentinel lymph nodes (SLNs).<sup>1</sup> The long-term follow-up data from the Z0011 study also revealed that the 10-year overall survival (OS) and disease-free survival (DFS) rates for patients who underwent SLND alone were not inferior to those for patients who underwent ALND.<sup>2</sup> Furthermore, SLND alone provided excellent loco-regional control based on early and late recurrence rates.<sup>3,4</sup>

The Z0011 results have led to a change in the standard axillary management of breast cancer.<sup>5-7</sup> However, the Z0011 study was closed early because of the excellent outcomes, and subanalyses were not completed for various conditions. Furthermore, the Z0011 results have not been validated in a larger cohort with a balance of patients who did or did not undergo ALND. Moreover, the studies that have validated the utility of the Z0011 strategy were performed using mostly Western populations.<sup>8-11</sup> Thus, as breast cancers in Asian women exhibit substantially different characteristics from those in Western patients,<sup>12</sup> the feasibility of the Z0011 strategy in the Asian population remains unclear. In addition, no studies have evaluated potential confounding that could be attributed to the total number of SLNs in the Z0011 study, which omitted ALND based on the presence of 1–2 metastatic SLNs, regardless of pathological confirmation when the patient had 1–2 SLNs. Caution must be exercised when applying the Z0011 strategy to those patients, as a small number of total SLNs does not guarantee a lower metastatic burden in the axillary nodes. Therefore, the present study aimed to validate the Z0011 results within a large Z0011-eligible cohort of Korean patients. As a secondary aim, this study

also aimed to investigate whether ALND omission among Z0011-eligible patients with  $\leq 2$  SLNs was associated with poorer outcomes.

## **METHODS**

### ***Selection of the Z0011-eligible cohort***

This retrospective study evaluated data from breast cancer databases that were prospectively maintained by five Korean teaching hospitals: Asan Medical Center, National Cancer Center, Samsung Medical Center, Seoul National University Hospital, and Severance Hospital. From these databases, we selected Z0011-eligible patients who were treated during 2010–2016 and fulfilled the eligibility criteria of the ACOSOG Z0011 trial. In general, these women had T1–T2 clinically node-negative invasive breast cancer, had undergone BCT, and had 1–2 positive SLNs based on routine hematoxylin and eosin staining; the detailed inclusion and exclusion criteria were the same as those for the ACOSOG Z0011 trial.<sup>1</sup> The Z0011-eligible Korean patients were subdivided according to whether the patients underwent SLND alone (the “SLND alone” group) or conventional ALND after SLND (the “ALND” group). The ALND procedure was defined as anatomical level I and II dissection that included  $\geq 10$  nodes. The SLNs were defined as the lymph nodes (LNs) that were identified using a blue dye and/or radioactive tracer. Whole-breast radiation therapy (RT) was planned for all women, and adjuvant systemic therapy had been selected by the physician and patient while being mindful of the ACOSOG Z0011 trial results.

### ***Study end-point***

The primary end-point was defined as disease recurrence, which included all types of recurrence (local, regional, and distant recurrence). Patients were followed via their medical records until October 2017 to identify any disease recurrence. The interval to recurrence was measured from the time of surgery to the first development of loco-regional or distant recurrence. Patients without confirmed recurrence at the time of analysis were censored at the date of their last follow-up.

## ***Statistical analyses***

The two groups' categorical and continuous characteristics were compared using the chi-square test and two-sample t-test. Survival curves were compared using the Kaplan-Meier method and log-rank test. Cox's proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) in order to assess the univariable and multivariable associations of recurrence with the prognostic variables and treatments.

Propensity score (PS)-matched analyses were performed to reduce possible selection biases. The PSs were calculated using a logistic regression model with omission of ALND as a dependent variable, and other independent variables were selected based on their potential association with ALND omission via univariable analyses. The cases (SLND alone group) and controls (ALND group) were paired 1:1 based on these PSs using the nearest-neighbor matching method. Standardized differences were estimated before and after the matching to evaluate the balance of the covariates, with small absolute values of  $<0.1$  considered indicative of balance between the cohorts.<sup>13, 14</sup> All statistical tests were two-sided and a *P*-value of  $\leq 0.05$  was considered statistically significant. The analyses were performed using IBM SPSS software (version 20.0; IBM Corp., Armonk, NY, USA) and SAS software (version 9.3; SAS Institute, Cary, NC, USA).

## RESULTS

### *Characteristics of the Korean Z0011-eligible cohort*

Between January 2010 and December 2016, 1,750 Korean patients fulfilled the Z0011 eligibility criteria, had undergone BCT, and had 1–2 SLN metastases. The baseline characteristics of the Korean Z0011-eligible cohort are summarized in Table 1. The median age was 49 years, the median tumor size was 2.1 cm, and 83.4% of the patients had estrogen receptor (ER)-positive cancers. The adjuvant treatments were chemotherapy (87.1% of patients) and RT (96.1% of patients), with endocrine therapy provided for all ER-positive cancers and for ER-negative but progesterone receptor (PR)-positive cancers. The median follow-up period was 50 months (range: 7–84 months).

The cohort was subdivided into 990 patients (57%) who had undergone ALND and 707 patients (40%) who underwent SLND alone. Fifty-three patients (3%) were excluded from the analyses because they had undergone SLND plus ALND but the extent of the dissection was confined to level I. There was no incremental increase in the ALND omission rate according to the year (2010–2016) in which the patients were treated. Although they were selected based on the Z0011 criteria, the Korean Z0011-eligible cohort had slightly different clinical and tumor characteristics. For example, the patients from the Korean Z0011-eligible cohort were younger, had larger and higher-grade tumors, and exhibited more frequent lymphovascular invasion than the original Z0011 participants (Table 2). Among the 1,750 Korean Z0011-eligible patients, 967 patients (55%) had  $\leq 2$  SLNs removed via SLND, although the characteristics of this sub-cohort were not different from those of the entire cohort (Table 3).

**Table 1. Baseline characteristics of the Z0011-eligible patients**

	Total No. (%)	SLND alone No. (%)	ALND No. (%)	ALND omission	<i>P</i> -value
Subject number	1,750	707	990	40.4%	
Patient age, years (range)	49 (25-92)	50 (25-88)	50 (25-88)		0.426
≤50	982 (56.1)	399 (56.4)	553 (55.9)	40.6%	
>50	768 (43.9)	308 (43.6)	437 (44.1)	40.1%	
BMI, mean (Kg/m <sup>2</sup> )	24.8	23.3	26.0		0.003
≤23.0	817 (46.7)	360 (50.9)	435 (43.9)	44.1%	
>23.0	933 (53.3)	347 (49.1)	555 (56.1)	37.2%	
Tumor size, mean (cm)	2.1	2.0	2.2		<.001
T category					<.001
T1	983 (56.2)	447 (63.2)	502 (50.7)	45.5%	
T2	767 (43.8)	260 (36.8)	488 (49.3)	33.9%	
N category					<.001
N1mi	229 (13.0)	184 (26.0)	42 (4.2)	80.6%	
N1	1,393 (79.6)	520 (73.6)	824 (83.2)	34.4%†	
N2	114 (6.5)	3 (0.4)	110 (11.1)		
N3	14 (0.8)		14 (1.4)		
No. of positive SLN					<.001
1	1,458 (83.3)	646 (91.4)	763 (77.1)	44.3%	
2	292 (16.7)	61 (8.6)	227 (22.9)	20.9%	
No. of total SLNs, mean	2.9	3.2	2.7		<.001
total SLNs≥3	783 (44.7)	353 (50.0)	420 (42.4)	45.1%	
total SLNs≤2	967 (55.3)	354 (50.0)	570 (57.6)	36.6%	
Axillary sonographic finding					0.015
normal	1586 (90.7)	657 (92.9)	884 (89.4)	41.4%	
suspicious	163 (9.3)	50 (7.1)	105 (10.6)	30.7%	
missing	1	0	1		
Histologic grade					0.013
1	223 (12.8)	112 (16.0)	111 (11.3)	50.2%	
2	986 (56.8)	401 (57.2)	552 (56.2)	40.7%	
3	527 (30.4)	188 (26.8)	319 (32.5)	35.7%	
missing	14	6	8		
Ki-67					0.149
≤20%	1,268 (72.6)	537 (76.1)	708 (71.6)		
>20%	479 (27.4)	169 (23.9)	281 (28.4)		
missing	3	1	1		
Lymphovascular invasion					0.022
present	818 (47.0)	301 (42.9)	490 (49.6)		
absent	924 (53.0)	401 (57.1)	497 (50.4)		
missing	8	5	3		
ER status					0.031
positive	1,459 (83.4)	606 (85.7)	814 (82.2)		

negative	291 (16.6)	101 (14.3)	176 (17.8)	
PR status				0.005
positive	1,303 (74.5)	552 (78.1)	718 (72.5)	
negative	447 (25.5)	155 (21.9)	272 (27.5)	
HER2 status				0.037
positive	281 (16.2)	108 (15.3)	167 (17.1)	
negative	1,453 (83.8)	597 (84.7)	809 (82.9)	
missing	16	2	14	
Molecular subtype				
luminal	1,459 (84.1)	606 (86.0)	814 (83.4)	
ER+, HER2-	1,278 (73.7)	539 (76.5)	705 (72.2)	
ER+, HER2+	166 (9.6)	66 (9.4)	95 (9.7)	
HER2	115 (6.6)	42 (6.0)	72 (7.4)	
triple negative	175 (10.1)	58 (8.2)	104 (10.7)	
missing	16	2	14	
Histologic type				0.170
IDC	1,611 (92.1)	644 (91.1)	916 (92.5)	
ILC	67 (3.8)	37 (5.2)	29 (2.9)	
IDC and ILC	25 (1.4)	7 (1.0)	18 (1.8)	
others	47 (2.7)	19 (2.7)	27 (2.7)	
Adjuvant therapy				
chemotherapy	1,525 (87.1)	578 (81.8)	896 (90.5)	<.001
radiation therapy	1,682 (96.1)	681 (96.3)	948 (95.8)	0.656
endocrine therapy	1,461 (83.5)	601 (85.0)	823 (83.1)	0.528
Median follow-up, months (IQR)	50 (31-63)	40 (26-57)	56 (36-67)	
Recurrence, total	95 (5.4)	24 (3.4)	66 (6.7)	
axilla	7 (0.4)	2 (0.3)	4 (0.4)	
ipsilateral breast	22 (1.3)	6 (0.8)	14 (1.4)	
distant organ	66 (3.8)	16 (2.3)	48 (4.8)	

Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; SLN, sentinel lymph node.

† The proportion of ALND omission was calculated from all patients with macrometastases (N1-3 categories) as a whole

**Table 2. Comparison between the Z0011-eligible cohort in this study and the ACOSOG Z0011 study cohort**

	Total	SLND alone	ACOSOG Z0011 (Intention-to-Treat sample)	
	No. (%)	No. (%)	SLND alone No. (%)	ALND No. (%)
Subject number	1,750	707	436	420
Patient age, years (range)	49 (25-92)	50 (25-88)	54 (25-90)	56 (24-92)
≤50	982 (56.1)	399 (56.4)	160 (36.7)	135 (32.1)
>50	768 (43.9)	308 (43.6)	266 (61.0)	278 (66.2)
missing			10	7
Tumor size, mean (cm)	2.1	2.0	1.6	1.7
T1	983 (56.2)	447 (63.2)	303 (70.6)	284 (67.9)
T2	767 (43.8)	260 (36.8)	126 (29.4)	134 (32.1)
N category				
N1mi	227 (13.0)	183 (25.9)	382 (92.1)	292 (85.1)
N1	1,393 (79.6)	520 (73.6)		
N2	114 (6.5)	3 (0.4)	4 (1.0)	47 (13.7)
N3	14 (0.8)			
missing			21	77
Number of positive SLN				
0			29 (7.0)	4 (1.2)
1	1,458 (83.3)	646 (91.4)	295 (71.1)	199 (58.0)
2	292 (16.7)	61 (8.6)	76 (18.3)	68 (19.8)
≥3			15 (3.6)	72 (21.0)
missing			21	77
Histologic grade				
1	223 (12.8)	112 (16.0)	81 (25.6)	71 (22.0)
2	986 (56.8)	401 (57.2)	148 (46.8)	158 (48.9)
3	527 (30.4)	188 (26.8)	87 (27.5)	94 (29.1)
missing	14	6	120	97
Lymphovascular invasion				
present	818 (47.0)	301 (42.9)	113 (35.2)	129 (40.6)
absent	924 (53.0)	401 (57.1)	208 (64.8)	189 (59.4)
missing	8	5	115	102
ER status				
positive	1,459 (83.4)	606 (85.7)	324 (82.7)	317 (82.7)
negative	291 (16.6)	101 (14.3)	68 (17.3)	66 (17.3)
missing			44	37
PR status				
positive	1,303 (74.5)	552 (78.1)	274 (69.9)	259 (67.6)
negative	447 (25.5)	155 (21.9)	118 (30.1)	124 (32.4)
missing			44	37
Histologic type				
IDC	1,611 (92.1)	644 (91.1)	356 (84.0)	344 (82.7)
ILC	67 (3.8)	37 (5.2)	36 (8.5)	27 (6.5)
IDC and ILC	25 (1.4)	7 (1.0)	-	-
others	47 (2.7)	19 (2.7)	32 (7.5)	45 (10.8)
missing			12	4
Adjuvant treatment				
chemotherapy	1,525 (87.1)	578 (81.8)	253 (58.0)	243 (57.9)

radiation therapy	1,682 (96.1)	681 (96.3)	277 (89.6)	263 (88.9)
endocrine therapy	1,461 (83.5)	601 (85.0)	203 (46.6)	195 (46.4)
Recurrence†, total	95 (5.4)	24 (3.4)		
axilla	7 (0.4)	2 (0.3)	4 (0.9)	2 (0.5)
ipsilateral breast	22 (1.3)	6 (0.8)	8 (1.9)	14 (3.6)
distant organ	66 (3.8)	16 (2.3)		

Abbreviations: ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; SLN, sentinel lymph node.

† The number of loco-regional recurrences in the Z0011 trial was the reported one at the median follow-up time of 6.3 years.

**Table 3. Baseline characteristics of the patients who had 2 or less sentinel lymph nodes**

	Total No. (%)	SLND alone No. (%)	ALND No. (%)	ALND omission	<i>P</i> -value
Subject number	967	354	570	36.6%	
Patient age, years	51 (27-88)	51 (29-82)	51 (27-88)		0.946
≤50	530 (54.8)	193 (54.5)	313 (54.9)	36.4%	
>50	437 (45.2)	161 (45.5)	257 (45.1)	36.8%	
BMI, average (Kg/m <sup>2</sup> )	26.0	23.3	27.7		0.017
≤23.0	434 (44.9)	177 (50.0)	239 (41.9)	40.8%	
>23.0	533 (55.1)	177 (50.0)	331 (58.1)	33.2%	
Tumor size, mean (cm)	2.1	2.0	2.2		<.001
T category					<.001
T1	534 (55.2)	225 (63.6)	280 (49.1)	42.1%	
T2	433 (44.8)	129 (36.4)	290 (50.9)	29.8%	
N category					<.001
N1mi	156 (16.1)	124 (35.0)	29 (5.1)	79.5%	
N1	730 (75.5)	229 (64.7)	462 (81.1)	28.4%†	
N2	68 (7.0)	1 (0.3)	66 (11.6)		
N3	13 (1.3)		13 (2.3)		
Number of positive SLN					<.001
1	868 (89.8)	339 (95.8)	489 (85.8)	39.1%	
2	99 (10.2)	15 (4.2)	81 (14.2)	15.2%	
Axillary sonographic finding					0.852
normal	912 (94.4)	335 (94.6)	541 (95.1)	36.7%	
suspicious	54 (5.6)	19 (5.4)	28 (4.9)	35.2%	
missing	1		1		
Histologic grade					0.005
1	122 (12.7)	57 (16.2)	65 (11.4)	46.7%	
2	559 (59.0)	211 (60.1)	321 (56.4)	37.7%	
3	282 (29.3)	83 (23.6)	183 (32.2)	29.4%	
missing	4	3	1		
Ki-67					0.092
≤20%	648 (67.1)	251 (71.1)	377 (66.1)		
>20%	318 (32.9)	102 (28.9)	193 (33.9)		
missing	1	1			
Lymphovascular invasion					0.022
present	498 (51.6)	162 (46.0)	31 (54.9)		
absent	467 (48.4)	190 (54.0)	257 (45.1)		
missing	2	2			
ER status					0.176
positive	801 (82.8)	302 (85.3)	466 (81.8)		
negative	106 (11.0)	52 (14.7)	104 (18.2)		
PR status					0.072

positive	723 (74.8)	278 (78.5)	417 (73.2)	
negative	244 (25.2)	76 (21.6)	153 (26.8)	
HER2 status				0.655
positive	160 (16.5)	56 (15.8)	99 (17.4)	
negative	795 (82.2)	297 (83.9)	460 (80.7)	
missing	12	1	11	
Molecular subtype				
luminal	789 (81.6)	301 (85.0)	455 (79.8)	
ER+, HER2-	702 (72.6)	269 (76.0)	404 (70.9)	
ER+, HER2+	87 (9.0)	32 (9.0)	51 (8.9)	
HER2	73 (7.5)	24 (6.8)	48 (8.4)	
triple negative	93 (9.6)	28 (7.9)	56 (9.8)	
missing	12	1	11	
Histologic type				0.089
IDC	893 (92.3)	321 (90.7)	530 (93.0)	
ILC	38 (3.9)	20 (5.6)	17 (3.0)	
IDC and ILC	8 (0.8)	1 (0.3)	7 (1.2)	
others	28 (2.9)	12 (3.4)	16 (2.8)	
Adjuvant treatment				
chemotherapy	826 (85.4)	283 (79.9)	501 (87.9)	0.002
radiation therapy	928 (96.0)	340 (96.0)	545 (95.6)	0.907
endocrine therapy	802 (82.9)	301 (85.0)	469 (82.3)	0.622
Median follow-up, months (IQR)	52 (32-64)	40 (26-58)	57 (36-68)	
Recurrence, total	53 (5.5)	9 (2.5)	40 (7.0)	
axilla	1 (0.1)	1 (0.3)	0 (0.0)	
ipsilateral breast	12 (1.2)	1 (0.3)	9 (1.6)	
distant organ	40 (4.1)	7 (2.0)	31 (5.5)	

Abbreviations: BMI, body mass index ( $\text{Kg}/\text{m}^2$ ); CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; SLN, sentinel lymph node.

† The proportion of ALND omission was calculated from all patients with macrometastases (N1-3 categories) as a whole

## ***Characteristics of the SLND alone group from the Korean Z0011-eligible cohort***

Among the Korean Z0011-eligible cohort, the 707 patients in the SLND alone group had smaller and lower-grade tumors than the ALND group. However, the SLND alone group still had larger and higher-grade tumors than the original Z0011 cohort (Table 2). Omission of ALND was more common for patients with T1 tumors than patients with T2 tumors (45.5% vs. 33.9%;  $P<.001$ ) and for lower-grade tumors than higher-grade tumors (histological grade 1: 50.2%, grade 2: 40.7%, grade 3: 35.7%;  $P<.001$ ). Omission of ALND was also more common for patients with 1 SLN metastasis than 2 SLN metastases (44.3% vs. 20.9%;  $P<.001$ ), for micro-metastasis than macro-metastasis (80.6% vs. 34.4%;  $P<.001$ ), and for  $>2$  total SLNs than  $\leq 2$  total SLNs (45.1% vs. 36.6%;  $P<.001$ ) (Table 1). Obesity and preoperative axillary sonographic findings might also affect surgeons' decision to omit ALND. Omission of ALND was more common for patients with a BMI of  $\leq 23$  kg/m<sup>2</sup> than a BMI of  $>23$  kg/m<sup>2</sup> (44.1% vs. 37.2%;  $P=.014$ ) and for patients with no suspicious nodes on preoperative axillary sonography than patients with suspicious nodes (47.3% vs. 26.4%;  $P<.001$ ).

Based on the policy of the Korean National Health Insurance Service, hormone receptor status and human epidermal growth factor receptor 2 (HER2) gene expression status are not usually determined before surgical treatment of breast cancer. Therefore, these factors were not considered as potentially affecting the decision to omit ALND.


### ***Outcomes in the Korean Z0011-eligible cohort***

Among the 1,750 patients, 95 patients (5.4%) experienced disease recurrence during a median follow-up period of 50 months, including 24 patients (3.4%) in the SLND alone group, 66 patients (6.7%) in the ALND group, and 5 patients who had been excluded because of incomplete ALND. Among the entire Korean Z0011-eligible cohort, the recurrences included 29 cases (1.7%) of loco-regional recurrence (LRR) and 66 cases (3.8%) of distant recurrence. Among the 29 LRRs, 8 cases (1.1%) occurred in the SLND alone group and 18 cases (1.8%) occurred in the ALND group. Among the 66 distant recurrences, 15 cases (2.3%) occurred in the SLND alone group and 48 cases (4.8%) occurred in the ALND group (Table 1). The median follow-up periods were 40 months for the SLND alone group and 56 months for the ALND group. The original Z0011 study revealed 5-year cumulative LRR incidences of 3.3% in the SLND alone group and 4.0% in the ALND group,<sup>4</sup> which were comparable to our incidences of LRR despite the noticeably poorer tumor characteristics in the present study.

Disease recurrence in the SLND alone group was not significantly different from that in the ALND group (unadjusted HR: 0.672, 95% CI: 0.420–1.076; Figure 1A). In the univariable analyses, significant differences in disease recurrence were observed according to T category, histological grade, lymphovascular invasion, Ki-67 expression, ER status, PR status, and RT treatment. No significant difference in recurrence was observed according to the number (1 vs. 2) or size (micro vs. macro) of metastatic SLNs, despite the noticeably different rates of ALND omission in those subgroups. Furthermore, ALND omission did not significantly influence disease recurrence in a model that included T category (T1 vs. T2), histological grade (1–2 vs. 3), lymphovascular invasion (absent vs. present), Ki-67 expression (>20% vs. ≤20%), ER status (negative vs. positive), PR status (negative vs. positive), and RT treatment (no vs. yes). In that model, patients who did not undergo ALND had an adjusted HR for disease recurrence of 0.848 (95% CI: 0.525–1.370). The multivariable analyses revealed that recurrence was significantly influenced by T category, lymphovascular invasion, Ki-67 expression, and RT treatment. Histologic grade was highly correlated with the presence of lymphovascular invasion and Ki-67

expression level. Additionally, ER and PR status were correlated with T category. There might be confounding effects between those variables arising from a specific biologic feature of tumor. ER, PR status and histologic grade were not significant risk factors for disease recurrence in the model for multivariable analyses (Table 4).

**Figure 1.** Cumulative incidence of disease recurrence by type of axillary surgery in (A) the entire Z0011-eligible patients; (B) the patients who had  $\leq 2$  sentinel lymph nodes.



Abbreviations: ALND, axillary lymph node dissection; SLND, sentinel lymph node dissection  
OS, overall survival.

**Table 4. Multivariable analysis for disease recurrence among the entire Z0011-eligible patients**


Variable	Univariable analysis		Multivariable analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Extent of axillary clearance		0.098		0.501
ALND	1.00 [Reference]		1.00 [Reference]	
SLNB alone	0.672 (0.420-1.076)		0.848 (0.525-1.370)	
No. of metastatic SLN		0.633		
1	1.00 [Reference]			
2	1.137 (0.671-1.928)			
Size of metastatic SLN		0.178		
micro-	1.00 [Reference]			
macro-	1.648 (0.797-3.408)			
T category		<.001		0.001
T1	1.00 [Reference]		1.00 [Reference]	
T2	2.773 (1.774-4.332)		2.172 (1.361-3.467)	
Histologic grade		<.001		0.393
1,2	1.00 [Reference]		1.00 [Reference]	
3	2.153 (1.416-3.274)		1.235 (0.760-2.007)	
Lymphovascular invasion		0.001		0.030
absent	1.00 [Reference]		1.00 [Reference]	
present	2.117 (1.364-3.287)		1.667 (1.051-2.645)	
Ki-67		<.001		0.039
≤20%	1.00 [Reference]		1.00 [Reference]	
>20%	2.350 (1.541-3.584)		1.618 (1.026-2.554)	
ER status		0.003		0.982
negative	1.00 [Reference]		1.00 [Reference]	
positive	0.496 (0.313-0.787)		1.008 (0.482-2.110)	
PR status		0.002		0.173
negative	1.00 [Reference]		1.00 [Reference]	

positive	0.515 (0.336-0.789)		0.635 (0.330-1.220)
HER2 status		0.289	
negative	1.00 [Reference]		
positive	0.700 (0.362-1.353)		
Adjuvant chemotherapy		0.316	
yes	1.00 [Reference]		
no	1.366 (0.742-2.515)		
Adjuvant radiation therapy		<.001	<.001
yes	1.00 [Reference]		1.00 [Reference]
no	8.813 (5.123-15.163)		6.408 (3.679-11.161)

Abbreviations: ALND, axillary lymph node dissection; ER, estrogen receptor; NS, not significant; PR, progesterone receptor; SLND, sentinel lymph node dissection

We also performed subgroup analyses according to hospital, age, BMI, T category, histological grade, ER status, PR status, HER2 gene expression status, Ki-67 expression, lymphovascular invasion, preoperative axillary sonographic finding, and adjuvant therapy. Omission of ALND did not increase the risk of disease recurrence within any of these subgroups (Table 5).

**Table 5. Risk of disease recurrence in each subgroup of the entire Z0011-eligible patients according to the clinicopathologic risk factors**



Abbreviations: BMI, body mass index ( $\text{Kg}/\text{m}^2$ ); CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.

The SLND alone and ALND groups were also compared among the 967 Z0011-eligible Korean patients with  $\leq 2$  SLNs. In those analyses, ALND omission did not significantly influence disease recurrence in the univariable analysis (unadjusted HR: 0.489, 95% CI: 0.236–1.011; Figure 1B) or in the multivariable analysis (adjusted HR: 0.605, 95% CI: 0.289–1.269). However, the multivariable analyses confirmed that disease recurrence was significantly influenced by T category, Ki-67 expression, and RT treatment. Similar to the main analyses, ER, PR status, histologic grade, and lymphovascular invasion were not significant risk factors for disease recurrence in that model (Table 6). Subgroup analyses of the 967 patients with  $\leq 2$  SLNs revealed that ALND omission did not increase the risk of disease recurrence in any of the subgroups (Table 7).


**Table 6. Multivariable analysis for disease recurrence among the patients who had 2 or less sentinel lymph nodes**

Variable	Univariable analysis		Multivariable analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Extent of axillary clearance				
ALND	1.00 [Reference]		1.00 [Reference]	
SLND alone	0.489 (0.236-1.011)	0.052	0.605 (0.289-1.269)	0.184
No. of metastatic SLN				
1	1.00 [Reference]			
2	1.205 (0.513-2.831)	0.666		
Size of metastatic SLN				
micro-	1.00 [Reference]			
macro-	1.725 (0.683-4.359)	0.251		
T category				
T1	1.00 [Reference]		1.00 [Reference]	
T2	3.395 (1.800-6.402)	<.001	2.542 (1.306-4.947)	0.006
Histologic grade				
1,2	1.00 [Reference]		1.00 [Reference]	
3	2.556 (1.448-4.511)	0.001	1.403 (0.722-2.729)	0.318

Lymphovascular invasion				
absent	1.00 [Reference]		1.00 [Reference]	
present	1.707 (0.948-3.076)	0.073	1.188 (0.634-2.228)	0.590
Ki-67				
≤20%	1.00 [Reference]		1.00 [Reference]	
>20%	2.732 (1.543-4.836)	0.001	2.042 (1.098-3.799)	0.024
ER status				
negative	1.00 [Reference]		1.00 [Reference]	
positive	0.563 (0.299-1.063)	0.076	1.107 (0.376-3.261)	0.854
PR status				
negative	1.00 [Reference]		1.00 [Reference]	
positive	0.558 (0.310-1.007)	0.052	0.730 (0.273-1.949)	0.530
HER2 status				
negative	1.00 [Reference]			
positive	0.645 (0.255-1.629)	0.356		
Adjuvant chemotherapy				
yes	1.00 [Reference]			
no	1.650 (0.798-3.414)	0.177		
Adjuvant radiation therapy				
yes	1.00 [Reference]		1.00 [Reference]	
no	5.409 (2.297-12.736)	<.001	3.601 (1.509-9.595)	0.004

Abbreviations: ALND, axillary lymph node dissection; ER, estrogen receptor; NS, not significant; PR, progesterone receptor; SLND, sentinel lymph node dissection

**Table 7. Risk of disease recurrence in each subgroup of the Z0011-eligible patients who had 2 or less sentinel lymph nodes according to the clinicopathologic risk factors**



Abbreviations: ALND, axillary lymph node dissection; BMI, body mass index (Kg/m<sup>2</sup>); CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.

### ***Comparison of disease recurrence after PS matching***

Given that some patient and tumor characteristics could influence the decision to omit ALND, we performed PS matching to reduce selection biases. Among the 1,750 Z0011-eligible patients, 111 patients were excluded based on missing data regarding the matching variables, and PS matching was performed for the remaining 1,639 patients (687 patients in the SLND alone group and 952 patients in the ALND group). The PSs were calculated using a logistic regression model with ALND omission as the dependent variable and the following independent variables: hospital, age ( $\leq 50$  years,  $> 50$  years), obesity ( $\leq 23.0$  kg/m<sup>2</sup>,  $> 23.0$  kg/m<sup>2</sup>), T category, number of positive SLNs, histological type, histological grade, ER status, PR status, HER2 gene expression status, Ki-67 expression ( $\leq 20\%$ ,  $> 20\%$ ), lymphovascular invasion, preoperative axillary sonographic findings (normal, suspicious), and RT treatment. After excluding 397 unmatched patients, we identified 1,242 PS-matched patients (621 patients in the SLND alone group, 621 patients in the ALND group). Similarly, we identified 660 PS-matched patients (330 patients in the SLND alone group, 330 patients in the ALND group) among the 895 Z0011-eligible patients with  $\leq 2$  SLNs. The standardized differences before and after the PS matching are summarized in Tables 8 and 9.

**Table 8. Standardized differences before and after propensity Score matching for the entire Z0011-eligible cohort**

	Before propensity score matching (n=1639)			After propensity score matching (n=1242)		
	SLND alone	ALND	Standard differen ce	SLND alone	ALND	Standard differen ce
<b>Hospital</b>			0.20288			0.04019
A	106 (15.43)	138 (14.5)		86 (13.85)	87 (14.01)	
B	183 (26.64)	297 (31.2)		172 (27.7)	176 (28.34)	
C	170 (24.75)	174 (18.28)		154 (24.8)	147 (23.67)	
D	180 (26.2)	244 (25.63)		162 (26.09)	168 (27.05)	
E	48 (6.99)	99 (10.4)		47 (7.57)	43 (6.92)	
<b>Patient age, years</b>			0.00528			-0.04219
>50	302 (43.96)	416 (43.7)		266 (42.83)	279 (44.93)	
≤50	385 (56.04)	536 (56.3)		355 (57.17)	342 (55.07)	
<b>BMI, Kg/m<sup>2</sup></b>			-0.12564			-0.02256
>23.0	338 (49.2)	528 (55.46)		316 (50.89)	323 (52.01)	
≤23.0	349 (50.8)	424 (44.54)		305 (49.11)	298 (47.99)	
<b>T category</b>			-0.22365			-0.00658
T2	255 (37.12)	458 (48.11)		247 (39.77)	249 (40.1)	
T1	432 (62.88)	494 (51.89)		374 (60.23)	372 (59.9)	
<b>No. of Positive SLN</b>			0.41573			0.01098
1	629 (91.56)	730 (76.68)		563 (90.66)	561 (90.34)	
2	58 (8.44)	222 (23.32)		58 (9.34)	60 (9.66)	
<b>Histologic type</b>			0.14068			0.06270
IDC	627 (91.27)	888 (93.28)		581 (93.56)	571 (91.95)	
ILC	34 (4.95)	25 (2.63)		18 (2.9)	23 (3.7)	
IDC and ILC etc.	7 (1.02)	17 (1.79)		7 (1.13)	9 (1.45)	
	19 (2.77)	22 (2.31)		15 (2.42)	18 (2.9)	
<b>Histologic grade</b>			-0.11899			0.04359
3	185 (26.93)	308 (32.35)		173 (27.86)	161 (25.93)	
1,2	502 (73.07)	644 (67.65)		448 (72.14)	460 (74.07)	
<b>ER status</b>			0.09521			-0.00911
positive	589 (85.74)	783 (82.25)		529 (85.19)	531 (85.51)	
negative	98 (14.26)	169 (17.75)		92 (14.81)	90 (14.49)	
<b>PR status</b>			0.12279			-0.00771
positive	535 (77.87)	691 (72.58)		480 (77.29)	482 (77.62)	
negative	152 (22.13)	261 (27.42)		141 (22.71)	139 (22.38)	
<b>HER2 overexpress ion</b>			-0.05673			-0.01797
positive	104 (15.14)	164 (17.23)		92 (14.81)	96 (15.46)	
negative	583 (84.86)	788 (82.77)		529 (85.19)	525 (84.54)	
<b>Ki-67</b>			-0.09766			-0.00372
>20%	164 (23.87)	268 (28.15)		155 (24.96)	156 (25.12)	

≤20%	523 (76.13)	684 (71.85)	466 (75.04)	465 (74.88)	
<b>Lymphovascular invasion</b>			-0.12291		-0.00647
present	295 (42.94)	467 (49.05)	278 (44.77)	280 (45.09)	
absent	392 (57.06)	485 (50.95)	343 (55.23)	341 (54.91)	
<b>Preoperative axillary sonography</b>			-0.12475		-0.01784
suspicious	48 (6.99)	100 (10.5)	48 (7.73)	51 (8.21)	
normal	639 (93.01)	852 (89.5)	573 (92.27)	570 (91.79)	
<b>Adjuvant radiation therapy</b>			-0.00075		-0.00947
no	23 (3.35)	32 (3.36)	18 (2.9)	19 (3.06)	
yes	664 (96.65)	920 (96.64)	603 (97.1)	602 (96.94)	

Abbreviations: ALND; axillary lymph node dissection; BMI, body mass index (Kg/m<sup>2</sup>); CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; SLN, sentinel lymph node.

**Table 9. Standardized differences before and after propensity score matching for the patients who had  $\leq 2$  SLNs among the Z0011-eligible cohort**


	Before propensity score matching (n=895)			After propensity score matching (n=660)		
	SLND alone	ALND	Standardized difference	SLND alone	ALND	Standardized difference
<b>Hospital</b>	0.20633			0.07933		
A	82 (23.7)	93 (16.94)		72 (21.82)	65 (19.7)	
B	129 (37.28)	233 (42.44)		125 (37.88)	123 (37.27)	
C	86 (24.86)	126 (22.95)		85 (25.76)	95 (28.79)	
D	25 (7.23)	42 (7.65)		24 (7.27)	25 (7.58)	
E	24 (6.94)	55 (10.02)		24 (7.27)	22 (6.67)	
<b>Patient age, years</b>	0.01354			-0.01823		
>50	158 (45.66)	247 (44.99)		151 (45.76)	154 (46.67)	
$\leq 50$	188 (54.34)	302 (55.01)		179 (54.24)	176 (53.33)	
<b>BMI, Kg/m<sup>2</sup></b>	-0.15947			-0.00606		
>23.0	173 (50)	318 (57.92)		170 (51.52)	171 (51.82)	
$\leq 23.0$	173 (50)	231 (42.08)		160 (48.48)	159 (48.18)	
<b>T category</b>	0.26756			-0.03727		
T2	126 (36.42)	272 (49.54)		126 (38.18)	132 (40)	
T1	220 (63.58)	277 (50.46)		204 (61.82)	198 (60)	
<b>No. of Positive SLN</b>	0.35537			0.02822		
1	331 (95.66)	469 (85.43)		315 (95.45)	313 (94.85)	
2	15 (4.34)	80 (14.57)		15 (4.55)	17 (5.15)	
<b>Histologic type</b>	0.16732			0.07825		
IDC	315 (91.04)	512 (93.26)		308 (93.33)	302 (91.52)	
ILC	18 (5.2)	17 (3.1)		13 (3.94)	15 (4.55)	
IDC and ILC etc.	1 (0.29)	7 (1.28)		1 (0.3)	2 (0.61)	
	12 (3.47)	13 (2.37)		8 (2.42)	11 (3.33)	
<b>Histologic grade</b>	-0.198			0.05006		
3	81 (23.41)	177 (32.24)		81 (24.55)	74 (22.42)	
1,2	265 (76.59)	372 (67.76)		249 (75.45)	256 (77.58)	
<b>ER status</b>	0.08905			-0.00849		
positive	295 (85.26)	450 (81.97)		280	281 (85.15)	

negative	51 (14.74)	99 (18.03)	(84.85)	50 (15.15)	49 (14.85)	
<b>PR status</b>			0.11924			-0.00728
positive	271 (78.32)	402 (73.22)		256 (77.58)	257 (77.88)	
negative	75 (21.68)	147 (26.78)		74 (22.42)	73 (22.12)	
<b>HER2 overexpression</b>			-			0
positive	55 (15.9)	97 (17.67)	0.04744	52 (15.76)	52 (15.76)	
negative	291 (84.1)	452 (82.33)		278 (84.24)	278 (84.24)	
<b>Ki-67</b>			-0.0831			-0.01323
>20%	102 (29.48)	183 (33.33)		98 (29.7)	100 (30.3)	
≤20%	244 (70.52)	366 (66.67)		232 (70.3)	230 (69.7)	
<b>Lymphovascular invasion</b>			-			0.01213
present	161 (46.53)	296 (53.92)	0.14809	159 (48.18)	157 (47.58)	
absent	185 (53.47)	253 (46.08)		171 (51.82)	173 (52.42)	
<b>Preoperative axillary sonography</b>			-			-0.0534
suspicious	17 (4.91)	27 (4.92)	0.00022	16 (4.85)	20 (6.06)	
normal	329 (95.09)	522 (95.08)		314 (95.15)	310 (93.94)	
<b>Adjuvant radiation therapy</b>			-			0.01812
no	12 (3.47)	20 (3.64)	0.00944	10 (3.03)	9 (2.73)	
yes	334 (96.53)	529 (96.36)		320 (96.97)	321 (97.27)	

Abbreviations: ALND; axillary lymph node dissection; BMI, body mass index (Kg/m<sup>2</sup>); CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; SLN, sentinel lymph node.

Among the 1,242 overall PS-matched patients, the adjusted HR for disease recurrence after ALND omission was 0.949 (95% CI: 0.550–1.639). Among the 660 PS-matched patients with  $\leq 2$  SLNs, the adjusted HR for disease recurrence after ALND omission was 0.833 (95% CI: 0.342–2.029). These results agreed with our findings from the multivariable analyses and support a broader applicability of the Z0011 result to patients in whom SLND only detects a small number of SLNs. The adjusted HRs after PS matching are shown in Figure 2, with the reported HR for LRR from the ACOSOG Z0011 trial.<sup>4</sup>

**Figure 2.** Adjusted hazard ratios of omitting conventional axillary dissection, for disease recurrence after propensity score matching.



Abbreviations: ALND, axillary lymph node dissection; CI, confidence interval; HR, hazard ratio; SLN, sentinel lymph node; SLND, sentinel lymph node dissection OS, overall survival.

## DISCUSSION

The present study retrospectively validated the safety of ALND omission in a large Korean Z0011-eligible cohort and evaluated whether the Z0011 strategy was feasible for patients with  $\leq 2$  SLNs. The relatively low proportion of ALND omission in the present cohort (40% among all patients) reflects an incomplete validation of the Z0011 result within a non-Western population, although that paradoxically facilitated a balanced study to compare ALND and no ALND. Relative to the Z0011 participants, the Korean Z0011-eligible patients had larger and higher-grade tumors and more frequent lymphovascular invasion, which may reflect racial differences between Asian and Western women. In this context, the characteristics of Asian Z0011-eligible patients have not been comprehensively evaluated, as previous studies involving Asian women have been limited by their small sample or non-omission of ALND.<sup>15, 16</sup> A recent Japanese study has also evaluated Japanese Z0011-eligible women and revealed, similar to the present study, that they had larger tumors and more frequent lymphovascular invasion than the Z0011 participants.<sup>15</sup> In contrast, validation studies that involved Western women have revealed tumor characteristics that were at least somewhat different from our findings.<sup>5, 11, 17</sup> Nevertheless, ours is the largest study to validate the Z0011 results among Asian women, and also provided a relatively balanced cohort of patients who did and did not undergo ALND.

The differences in tumor characteristics between the original Z0011 cohort and our Z0011-eligible cohort could be related to unexpected treatment selection based on preoperative axillary evaluations. For example, our cohort involved patients who routinely underwent axillary sonography, and this procedure might have allowed clinically node-negative patients to undergo upfront ALND or neoadjuvant systemic therapy, which would have resulted in these cases being excluded from the present study. However, the vast majority of patients who fulfilled the Z0011 criteria had a low burden of node metastasis, regardless of whether the metastatic LNs were detected via SLND or image-guided cytology. Wellington et al.<sup>18</sup> have also reported that the use of axillary sonography is unlikely to change the proportion of ALND, despite the possible administration of neoadjuvant chemotherapy. Moreover, the proportion of patients with

suspicious axillary findings did not differ between our study groups (Table 1). The possible exclusion of patients who had suspicious axillary findings is unlikely to be biased and would likely have minimal effect on our findings.

It is recommended that >10 LNs be acquired during conventional ALND to achieve an adequate axillary assessment during breast cancer staging. Similarly, the number of acquired SLNs during SLND is thought to influence the predictive quality and accuracy.<sup>19</sup> The reported false-negative rate of SLND is 6.7% with  $\geq 3$  SLNs, although this rate increases to 9.7% for 2 SLNs and 13.0% for 1 SLN,<sup>20</sup> and SLND only removes an average of 2 LNs in most studies.<sup>21-23</sup> Interestingly, although surgeons might be biased towards the removal of additional SLNs for Z0011-eligible patients, the median number of SLNs has not changed between pre- and post-Z0011 eras.<sup>24, 25</sup> To adequately apply the Z0011 strategy and improve the accuracy of SLND, surgeons may aim to harvest more SLNs. However, only  $\leq 2$  SLNs can be obtained in a considerable proportion of patients (e.g., 55% in our cohort). Thus, the applicability of the Z0011 results within this patient subgroup is a clinically significant issue, based on the relatively poor accuracy of SLND, that should be validated separately.

Our findings demonstrated that a small number of SLNs had a minimal impact on recurrence after Z0011-based treatment. This result may reflect the excellent outcomes among patients who fulfilled the Z0011 criteria. Furthermore, the present study included a higher proportion of patients who underwent adjuvant chemotherapies than the Z0011 study (87% vs. 58%), as well as a higher proportion of endocrine therapy for ER-positive cases (almost 100% vs. 79%). It is possible that the lower number of recurrences in the present study could be attributed to the higher proportion of adjuvant systemic therapy, although it may also be related to the ordinal position of the first positive LN among all removed SLNs. For example, Yi et al.<sup>19</sup> demonstrated that the “hottest” SLN during SLND was the first positive LN in 69% of the 777 patients with positive SLNs, and that the likelihood of metastatic disease decreased with each successive SLN, to the point that the first positive SLN was at the third or greater SLN in only 9% of cases with  $\geq 3$  LNs removed. In this context, the SLN is defined as the first LN in a regional lymphatic

basin to accept drainage from the primary tumor,<sup>26-28</sup> which suggests that latter SLNs are less likely to provide predictive value relative to the first one.

The present study's retrospective design raises the possibility of biases disguising poorer outcomes in the SLND alone group than in the ALND group. Furthermore, the inter-group differences suggested a possibility of selection bias affecting the decision to omit ALND (Table 1). Thus, to reduce those possible biases, we performed PS matching and re-evaluated the outcomes, although this failed to reveal a significant difference in recurrence in the PS-matched analyses. As the Z0011 trial results have been confirmed using long-term follow-up data and several validation studies, it appears reasonable to use a retrospective cohort study in place of a randomized controlled trial, and the use of PS matching is a useful approach to overcoming the inherent limitations of the retrospective design.

We selected disease recurrence as the present study's end-point, based on a median follow-up of 4 years and an 8-year interval from the Z0011 report. This is because our relatively short follow-up period is likely insufficient to identify a significant difference in mortalities, especially given the patients' excellent prognosis and the fact that we only detected 28 deaths (Table 1). We also detected fewer LRR events than in the Z0011 study, which makes this outcome inappropriate as a study end-point. Furthermore, distant recurrence frequently leads to death in most cases, and was more common than LRR (66 events vs. 29 events), which is why we combined both distance recurrences and LRRs as the study end-point. This approach is less ideal than evaluating DFS or OS as an end-point, although it is a better surrogate for survival than LRR alone. Moreover, evaluating disease recurrence among patients with early breast cancer remains clinically relevant (apart from survival analyses), as breast cancer-related mortality typically occurs later than recurrence.

The present study revealed median follow-up periods of 56 months in the ALND group and 40 months in the SLND alone group, which are relatively short given that Z0011-eligible patients have early-stage disease and typically ER-positive tumors. This is important, as patients with ER-positive breast cancer have a long-term risk of disease recurrence,<sup>29, 30</sup> and prolonged

follow-up is needed to determine whether there is a significant difference in late recurrence between the ALND and SLND alone groups. Nevertheless, additional follow-up from years 5 to 10 did not change the major findings of the Z0011 trial, despite most of the participants having ER-positive tumors. Furthermore, between years 5 and 10, only 11 additional LRRs were detected in the Z0011 cohort,<sup>3,4</sup> and the incremental decreases in DFS between years 5 and 10 (−3.7% for the SLND alone group and −4.0% for the ALND group) were not meaningfully different.<sup>1, 2</sup> Thus, based on the minimal changes during long-term follow-up of the Z0011 cohort, we do not believe that our findings are likely to change based on a prolonged follow-up interval.

## **CONCLUSION**

This retrospective cohort study of 1,750 Z0011-eligible Korean patients with breast cancer revealed that ALND could be omitted without increasing the risk of disease recurrence after a median follow-up of 50 months. This result was confirmed in PS-matched analyses to minimize the potential for selection biases. Furthermore, among patients with  $\leq 2$  SLNs removed, disease recurrence was not significantly different between the SLND alone group and the ALND group. These results suggest that the small number of SLNs had minimal impact on the risk of disease recurrence based on the approach of the ACOSOG Z0011 trial.

## REFERENCES

1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 2011; 305(6):569-75.
2. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. *JAMA* 2017; 318(10):918-926.
3. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. *Annals of Surgery* 2010; 252(3):426-32; discussion 432-3.
4. Giuliano AE, Ballman K, McCall L, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. *Annals of Surgery* 2016; 264(3):413-20.
5. Poodt IGM, Spronk PER, Vugts G, et al. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era. *Annals of Surgery* 2017.
6. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. *J Natl Compr Canc Netw* 2018; 16(5S):605-610.
7. Lyman GH, Somerfield MR, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. *J Oncol Pract* 2017; 13(3):196-198.
8. Delpech Y, Bricou A, Lousquy R, et al. The exportability of the ACOSOG Z0011

- criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study. *Annals of Surgical Oncology* 2013; 20(8):2556-61.
9. Yi M, Kuerer HM, Mittendorf EA, et al. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. *Journal of the American College of Surgeons* 2013; 216(1):105-13.
  10. Dengel LT, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. *Annals of Surgical Oncology* 2014; 21(1):22-7.
  11. Morrow M, Van Zee KJ, Patil S, et al. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients. *Annals of Surgery* 2017; 266(3):457-462.
  12. Bhoo-Pathy N, Yip CH, Hartman M, et al. Breast cancer research in Asia: adopt or adapt Western knowledge? *European Journal of Cancer* 2013; 49(3):703-9.
  13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009; 28(25):3083-107.
  14. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *J Clin Epidemiol* 2001; 54(4):387-98.
  15. Kittaka N, Tokui R, Ota C, et al. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. *Int J Clin Oncol* 2018.
  16. Liu M, Wang S, Cui S, et al. The feasibility of the ACOSOG Z0011 Criteria to Chinese Breast Cancer Patients: A Multicenter Study. *Scientific reports* 2015; 5:15241.
  17. Yao K, Liederbach E, Pesce C, et al. Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer. *Journal of the American College of*

- Surgeons* 2015; 221(1):71-81.
18. Wellington J, Sanders T, Mylander C, et al. Routine Axillary Ultrasound for Patients with T1-T2 Breast Cancer Does Not Increase the Rate of Axillary Lymph Node Dissection Based on Predictive Modeling. *Annals of Surgical Oncology* 2018; 25(8):2271-2278.
  19. Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? *Cancer* 2008; 113(1):30-7.
  20. Lee SA, Lee HM, Lee HW, et al. Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer. *Cancer Res Treat* 2018; 50(3):625-633.
  21. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol* 2014; 15(12):1303-10.
  22. Galimberti V, Cole BF, Zurrada S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. *Lancet Oncol* 2013; 14(4):297-305.
  23. Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. *European Journal of Surgical Oncology* 2017; 43(4):672-679.
  24. Robinson KA, Pockaj BA, Wasif N, et al. Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection? *American Journal of Surgery* 2014; 208(6):1060-4; discussion 1063-4.
  25. Subhedar P, Stempel M, Eaton A, et al. Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed? *Annals of Surgical Oncology* 2015; 22

Suppl 3:S470-5.

26. Cabanas RM. An approach for the treatment of penile carcinoma. *Cancer* 1977; 39(2):456-66.
27. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Archives of Surgery* 1992; 127(4):392-9.
28. Krag DN. Minimal access surgery for staging regional lymph nodes: the sentinel-node concept. *Current Problems in Surgery* 1998; 35(11):951-1016.
29. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet* 2011; 378(9793):771-84.
30. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med* 2010; 7(5):e1000279.

# 국 문 초 록

한국 여성 유방암 코호트에서 ACOSOG Z0011 연구 결과의 유효성 확인

**Retrospectively validating the results of the ACOSOG Z0011 trial in a large**

**Korean Z0011-eligible cohort**

유방암의 치료에 있어서 액와부 림프절 광청술의 역할은 다른 보조 치료의 발전과 더불어 점차 감소하고 있다. 2010년 보고된 Z0011 연구는 cT1-2N0 유방암에 대해 유방보존술 및 감시 림프절 생검을 시행하여 1-2개의 전이성 림프절이 발견되더라도 적절한 보조 치료가 시행될 예정이라면 액와부 광청술이 반드시 시행될 필요는 없다는 점을 국소 재발 및 생존률 측면에서 보여주었다. 이 연구 결과는 보다 대규모의 코호트 자료를 통해 제대로 검증된 적이 없으며, 특히 동양 여성의 유방암에서 동일하게 적용이 가능한 지에 대하여서는 거의 연구된 바가 없다. 따라서 본 연구는 한국인 여성 유방암 코호트 분석을 통해 Z0011 연구의 결과를 검증하는 한편 감시 림프절의 획득 개수로 대변되는 감시 림프절 생검의 질적 수준이 그에 영향을 주는지 평가하고자 하였다.

이를 위하여 수도권 5개 대형 삼차 병원의 유방암 데이터 베이스에서 Z0011 연구 결과 적용 기준에 맞는 환자 코호트를 구축하고 감시 림프절 생검 후 액와부 광청술을 시행한 그룹과 시행하지 않은 그룹간의 재발을 콕스 비례위험모델을 이용한 다변량 분석 및 성향 점수(Propensity Score) 매칭을 이용하여 비교하였다.

2010년부터 2016년까지 Z0011 기준에 맞는 유방암 환자는 총 1,750명이었으며, 그 중 707명에서는 액와부 광청술이 시행되지 않았고 967명에서는 액와부 광청술이 시행되었다. 50개월의 평균 관찰 기간 중 95례(5.4%)의 재발이 있었으며, 액와부 광청술의 시행 여부에 따른 재발의 차이를 보이지 않았다. 성향 점수 매칭을 통해 보정된 액와부 광청술의 생략으로 인한 위험도는 전체 코호트에서 0.95 (95% CI: 0.55-1.64)이었으며, 획득한 감시 림프절 개수가 2개 이하인 코호트에서 0.83 (95% CI: 0.34-2.03)이었다.

결론적으로 본 연구는 Z0011연구와 동일한 선정 기준을 통해 선별한 대규모 코호트 분석을 통해 한국 여성의 유방암에서도 Z0011연구 결과와 마찬가지로 액와부 광청술 여부에 따라 재발의 차이가 없음을 확인하였다. 또한, 획득한 감시 림프절 개수가 적더라도 이러한 연구 결과 적용에는 큰 영향이 없을 것으로 생각된다.

.....

**주요어 : 유방암, 액와부 광청술, 감시 림프절 생검**

**학 번 : 2016-21926**